Literature DB >> 26607722

The value of control conditions for evaluating pharmacogenetic effects.

Li-Shiun Chen1, Timothy B Baker2, Laura J Bierut1.   

Abstract

Mesh：

Year:  2015        PMID： 26607722      PMCID： PMC5558525          DOI： 10.2217/pgs.15.143

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  19 in total

1.  Prospective association of dopamine-related polymorphisms with smoking cessation in general care.

Authors:  Lutz P Breitling; Dorothee Twardella; Michael M Hoffmann; Stephanie H Witt; Jens Treutlein; Hermann Brenner
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

2.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

3.  CHRNA3 rs1051730 genotype and short-term smoking cessation.

Authors:  Marcus R Munafò; Elaine C Johnstone; Donna Walther; George R Uhl; Michael F G Murphy; Paul Aveyard
Journal:  Nicotine Tob Res       Date:  2011-06-20       Impact factor: 4.244

4.  Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.

Authors:  Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-01-25       Impact factor: 3.568

5.  Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials.

Authors:  Sue-Jane Wang; Robert T O'Neill; Hm James Hung
Journal:  Clin Trials       Date:  2010-07-01       Impact factor: 2.486

6.  Alpha-5 and -3 nicotinic receptor gene variants predict nicotine dependence but not cessation: findings from the COMMIT cohort.

Authors:  Chad A Bousman; Cheryl Rivard; Jason Den Haese; Christine Ambrosone; Andrew Hyland
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-01-05       Impact factor: 3.568

7.  Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region.

Authors:  Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Niloufar Ameli; Alan F Schatzberg; Greer M Murphy
Journal:  Nicotine Tob Res       Date:  2015-01-08       Impact factor: 4.244

8.  Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Authors:  Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

9.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.

Authors:  J L Mega; N O Stitziel; S Kathiresan; M S Sabatine; J G Smith; D I Chasman; M Caulfield; J J Devlin; F Nordio; C Hyde; C P Cannon; F Sacks; N Poulter; P Sever; P M Ridker; E Braunwald; O Melander
Journal:  Lancet       Date:  2015-03-04       Impact factor: 79.321

10.  Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Stevens S Smith; Charles Gu; Richard A Grucza; George Davey Smith; Marcus Munafo; Laura J Bierut
Journal:  Drug Alcohol Depend       Date:  2014-07-03       Impact factor: 4.492
View more
  1 in total

Review 1.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.